Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 RHHBY | Healthcare | $60.30 | 581.00K | $384.83B | 26.35 | 2.57% | Hold |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| RHHBY | Roche Holding | 60.30 | 16.22 | 36.79% |
| Name | Price | % Change | |
|---|---|---|---|
| RHHBY | $60.30 | +36.79% |
Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approval of Gazyva/Gazyvaro as an add-on therapy for the treatment
Citi raised the firm’s price target on Roche (RHHBY) to CHF 440 from CHF 400 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate
Roche (RHHBY) announced the U.S. FDA 510(k) clearance of the cobas eplex respiratory pathogen panel 3. Designed for the automated cobas eplex system, this flexible syndromic test offers up to
UBS analyst Matthew Weston downgraded Roche (RHHBY) to Neutral from Buy with a price target of CHF 420, up from CHF 376. The firm cites valuation following the stock’s recent
Roche (RHHBY) announced that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver reliable testing with a planned menu of
Get caught up quickly on the top news from the weekend this five Top Five list. Volkswagen’s (VWAGY) Audi announced plans to establish its first U.S. production site in Georgia.
Genentech, a member of the Roche (RHHBY) Group, announced results from the Phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor,
Jefferies raised the firm’s price target on Zymeworks (ZYME) to $52 from $50 and keeps a Buy rating on the shares. The company and Roche (RHHBY) entered into an exclusive
Ionis Pharmaceuticals (IONS) partner Roche (RHHBY) announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy receiving optimized standard of care, demonstrating
Roche (RHHBY) announced late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy receiving optimized standard of care, demonstrating that investigational sefaxersen achieved
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| RHHBY | Jan 28, 2027Before Open | $384.83B | $1.47 | $20.28B | 0.36 | 26.35 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
